Medline (NASDAQ:MDLN) Shares Down 10.5% – Here’s What Happened

Medline (NASDAQ:MDLN)’s share price traded down 10.5% during trading on Wednesday . The company traded as low as $39.85 and last traded at $40.5660. 2,978,371 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 5,252,056 shares. The stock had previously closed at $45.32.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported first-quarter 2026 results, with earnings per share of $0.33 beating estimates and revenue of $7.35 billion rising 10.7% year over year, supporting the case for continued business momentum. Medline Reports First Quarter 2026 Results
• Positive Sentiment: Jefferies initiated coverage with a Buy rating, adding to the bullish analyst tone around Medline and reinforcing expectations for further upside. Medline (MDLN) Receives a Buy from Jefferies
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and maintained a $55 price target, signaling confidence that Medline can recover from current levels. BTIG Research rating update
• Positive Sentiment: Bank of America Securities reiterated a Buy rating, saying margin pressures may be a near-term issue but that Medline’s growth outlook remains strong. Medline Maintained at Buy as Analyst Trims Price Target to $53
• Neutral Sentiment: Sanford C. Bernstein lowered its price target to $54 from $56 while keeping an Outperform rating, a small cautionary note that suggests the stock may face some valuation or margin headwinds. Bernstein price target update
• Neutral Sentiment: Medline also launched its AI-powered Mpower platform to improve supply chain resiliency, a strategic positive but likely not a near-term earnings driver. Medline launches AI-powered Mpower Platform

Analyst Ratings Changes

A number of brokerages have weighed in on MDLN. Robert W. Baird began coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price for the company. BMO Capital Markets lifted their target price on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Morgan Stanley lifted their target price on Medline from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Stifel Nicolaus set a $55.00 target price on Medline in a report on Wednesday, February 25th. Finally, Tigress Financial lifted their target price on Medline from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.69.

Medline Price Performance

The firm’s fifty day moving average is $44.40.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion for the quarter. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, equities analysts forecast that Medline will post 1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medline

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. bought a new stake in shares of Medline during the first quarter valued at approximately $93,000. Parallel Advisors LLC boosted its position in shares of Medline by 1,073.3% during the first quarter. Parallel Advisors LLC now owns 5,280 shares of the company’s stock valued at $235,000 after buying an additional 4,830 shares during the last quarter. Kera Capital Partners Inc. boosted its position in shares of Medline by 3.9% during the first quarter. Kera Capital Partners Inc. now owns 89,021 shares of the company’s stock valued at $3,961,000 after buying an additional 3,379 shares during the last quarter. Assetmark Inc. purchased a new position in shares of Medline during the first quarter valued at approximately $62,000. Finally, Bessemer Group Inc. boosted its position in shares of Medline by 39,404.0% during the first quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after buying an additional 3,495,136 shares during the last quarter.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.